𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adjuvant chemo(immuno-)-therapy of primary breast cancer with adriamycin-cyclophosphamide (and levamisole)—Six-year evaluation

✍ Scribed by Schreml, Wolfgang; Lang, Margarete; Betzler, Michael; Schlag, Peter; Lohrmann, Hans-Peter; Heimpel, Hermann; Herfarth, Christian

Book ID
123537634
Publisher
Elsevier Science
Year
1983
Weight
719 KB
Volume
19
Category
Article
ISSN
0277-5379

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized adjuvant trial to evaluate th
Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the nishi-nippon group of the adjuvant chemoendocrine therapy for breast cancer organization
✍ Masakazu Toil; Takao Hattori; Masanobu Akagi; Kiyoshi Lnokuchi; Kunzo Orita; Kei 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 714 KB

Background. A randomized adjuvant trial was conducted from October 1982 to January 1985 to evaluate the addition of tamoxifen (TAM) to combination chemotherapy with perioperative mitomycin C (MMC) and ftorafur (FT) for patients with estrogen receptor (ER)-positive tumors and the addition of PSK, a b

Evaluation of the worth of Corynebacteri
Evaluation of the worth of Corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer: Eight-year results from the national surgical adjuvant breast and bowel project B-10
✍ Bernard Fisher; Ann Brown; Norman Wolmark; Edwin R. Fisher; Carol Redmond; D. La 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 854 KB

During the 1970s, information obtained from animal tumor models and from patients with a spectrum of solid tumors indicated the worth of a variety of immunostimulating agents. These findings provided a biological and clinical rationale for conducting randomized trials to evaluate the worth of those

Adjuvant six cycles of high-dose adriamy
Adjuvant six cycles of high-dose adriamycin, cyclophosphamide, methotrexate, 5-fluorouracil (ACMF) vs. 12 cycles of low-dose acmf with tamoxifen for premenopausal, node-positive breast cancer patients: Results of a prospective randomized study
✍ Dr. Takashi Fukutomi; Sadako Akashi; Takeshi Nanasawa; Hiroshi Yamamoto 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 398 KB

A prospective randomized study was conducted to compare the adjuvant efficacy of six cycles of high-dose ACMF (Adriamycin, ADM; cyclophosphamide, CPA; methotrexate, MTX; 5-fluorouracil, 5-FU) with that of 12 cycles of low-dose ACMF in premenopausal, node-positive breast cancer patients. The six-cycl